New migraine drug shows promise in Real-World study
NCT ID NCT06409845
First seen Jun 11, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This study looked at how well eptinezumab works and how tolerable it is for preventing migraines. Researchers followed 130 people with episodic or chronic migraine who received quarterly infusions of eptinezumab. They tracked changes in monthly migraine days and the percentage of patients who had at least a 50% reduction in migraine days over 3 to 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
SISC
Florence, Florence, 50134, Italy
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eptinezumab
What this could lead to
If successful, this could confirm eptinezumab as a safe and effective option for reducing migraine frequency in people with episodic or chronic migraine.
What could go wrong
This is a completed observational study, not a large randomized trial. Results may not apply to all migraine patients, and side effects or lack of response are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.